S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma|
|Soligenix Expands Pipeline with Acquisition of Phase 3-Ready Oncology Clinical Program|
|Soligenix Announces Issuance of US Patent for ThermoVax™ Technology|
|Soligenix to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City|
|Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development|
|Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Revises Price Target Higher From $5.50 to $7.00|
|Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine|
|Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine|
|Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301, Synthetic Hypericin, for the Treatment of Cutaneous T-Cell Lymphoma|
Click above to view more mutual fund data and stats for sngx - Soligenix Inc.